– FRANCE, Paris – François Garnier has been appointed Executive Vice President, General Counsel for the Ipsen Group effective as of January 5, 2015. As such, he will sit on the Chairman’s Committee and on the Executive Committee.
François Garnier succeeds to Nathalie Joannes who wishes to give a new direction to her career.
Marc de Garidel, Chairman and CEO of Ipsen, said: “We are very happy to welcome François Garnier to the Ipsen Group. He has spent 25 years building his legal expertise in a number of pharmaceutical companies around the world. He brings his knowledge and international experience in the industry as additional major strengths to accelerate Ipsen’s growth.”
Previously, François Garnier was International Chief Counsel (outside the US) of Pfizer Inc. since January 2014. He joined Pfizer France, in April 2003, as Vice President, General Counsel before moving on to become Chief Counsel for Pfizer’s operations in Europe in January 2009, a position he held until January 2014. François Garnier began his career in March 1989 at Servier S.A. as International Contracts Manager and remained with the firm until September 1995. He then moved to Rhône Poulenc Rorer S.A. to take up the position of Counsel for Corporate Transactions. In May 1996, he moved to the United States as Associate Counsel, before being appointed Chief Counsel for France in May 1999. François Garnier continued his career as Chief Counsel at Aventis Animal Nutrition until September 2001, when he joined the Pharmacia Group as Chief Counsel for Europe.
Ipsen is a global specialty-driven pharmaceutical company with total sales exceeding €1.2 billion in 2013. Ipsen’s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by 3 franchises: neurology, endocrinology and uro-oncology. Moreover, the Group has an active policy of partnerships. Ipsen’s R&D is focused on its innovative and differentiated technological platforms, peptides and toxins. In 2013, R&D expenditure totaled close to €260 million, representing more than 21% of Group sales. Moreover, Ipsen also has a significant presence in primary care. The Group has close to 4,600 employees worldwide. Ipsen’s shares are traded on segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150) and eligible to the “Service de Règlement Différé” (“SRD”). The Group is part of the SBF 120 index. Ipsen has implemented a Sponsored Level I American Depositary Receipt (ADR) program, which trade on the over-the-counter market in the United States under the symbol IPSEY.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
Comments are closed.